A Study of ABT-751 in Patients With Recurrent Breast Cancer After Taxane (Taxol or Taxotere) Therapy.

Abbott40 enrolled

Overview

The purpose of the study is to determine if ABT-751 will decrease tumors, and determine how long the tumor shrinkage can be maintained in patients with breast cancer after having had taxol or taxotere. Patients will receive ABT-751 by mouth daily for 21 days. Patients will be off drug for 7 days before starting the next cycle of drug.

Study Type

INTERVENTIONAL

Allocation

NON_RANDOMIZED

Purpose

TREATMENT

Masking

NONE

Enrollment

Conditions

Breast Cancer

Interventions

ABT-751DRUG

Eligibility

Sex: FEMALEMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria * Stage IIIB or IV breast cancer. * Recurrent tumor after or while on taxane therapy (taxol or taxotere). * Able to tolerate normal activities of daily living. * Adequate bone marrow, kidney and liver function. Exclusion Criteria * Pregnant or breast feeding. * No anti-tumor therapy (including hormonal therapy or Herceptin) within 4 weeks of the start of ABT-751 administration.

Locations (8)

Oncology-Hematology Group of South Florida

Miami, Florida, United States

Clinical Research Network, Inc.

Plantation, Florida, United States

Georgia Cancer Specialists

Atlanta, Georgia, United States

Northwestern University Medical School Division of Hematology/Oncology

Outcomes

Primary Outcomes

Objective Response Rate in subjects with Breast cancer

Time frame: 1 year

Secondary Outcomes

Time to Tumor Progression (TTP)

Time frame: 1 year

Survival

Time frame: 2 years

Toxicities associated with treatment administration

Time frame: 1 year

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.